<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Isoniazid: An overview
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Isoniazid: An overview
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Isoniazid: An overview
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Richard H Drew, PharmD, MS, FCCP, FIDP
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            John Bernardo, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Elinor L Baron, MD, DTMH
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Dec 13, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="8577" href="/z/d/drug information/8577.html" rel="external">
          Isoniazid
         </a>
         (INH) is used for treatment of tuberculosis (as part of combination therapy) or for latent tuberculosis infection (as monotherapy or part of combination therapy). Less frequently, INH may be used as part of a combination regimen for nontuberculous mycobacterial infections.
        </p>
        <p>
         Basic issues related to clinical use of INH will be reviewed here. The clinical settings in which INH may be used are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/8015.html" rel="external">
          "Treatment of drug-susceptible pulmonary tuberculosis in nonpregnant adults without HIV infection"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8017.html" rel="external">
          "Treatment of tuberculosis infection (latent tuberculosis) in nonpregnant adults without HIV infection"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8013.html" rel="external">
          "Treatment of drug-susceptible pulmonary tuberculosis in nonpregnant adults with HIV infection: Initiation of therapy"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8011.html" rel="external">
          "Treatment of tuberculosis infection (latent tuberculosis) in nonpregnant adults with HIV infection"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5341.html" rel="external">
          "Treatment of
          <i>
           Mycobacterium avium
          </i>
          complex pulmonary infection in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H6642017">
         <span class="h1">
          PHARMACOLOGY
         </span>
        </p>
        <p class="headingAnchor" id="H6643120">
         <span class="h2">
          Mechanism of action
         </span>
         <span class="headingEndMark">
          —
         </span>
         The antimicrobial activity of INH is selective for mycobacteria, likely due to its ability to inhibit mycolic acid synthesis, which interferes with cell wall synthesis, thereby producing a bactericidal effect [
         <a href="#rid1">
          1
         </a>
         ]. INH also disrupts DNA, lipid, carbohydrate, and nicotinamide adenine dinucleotide (NAD) synthesis and/or metabolism.
        </p>
        <p class="headingAnchor" id="H6642420">
         <span class="h2">
          Spectrum of activity
         </span>
         <span class="headingEndMark">
          —
         </span>
         INH is active against intracellular and extracellular
         <em>
          Mycobacterium tuberculosis
         </em>
         . The organism is considered most susceptible to INH during its logarithmic phase of growth [
         <a href="#rid1">
          1
         </a>
         ]. The minimum inhibitory concentration (MIC) of
         <em>
          M. tuberculosis
         </em>
         for INH-susceptible isolates generally ranges from 0.03 to 0.125 mcg/mL [
         <a href="#rid2">
          2
         </a>
         ]. The MICs and minimum bactericidal concentrations (MBCs) for the organism are equivalent for most isolates [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
         Of the nontuberculous mycobacteria spp,
         <em>
          M. kansasii
         </em>
         and
         <em>
          M. xenopi
         </em>
         are considered the most susceptible, while
         <em>
          M. avium
         </em>
         complex is generally resistant to INH.
        </p>
        <p class="headingAnchor" id="H2197574631">
         <span class="h2">
          Resistance mechanisms
         </span>
         <span class="headingEndMark">
          —
         </span>
         Resistance to INH occurs through alteration in one of at least four pathways [
         <a href="#rid3">
          3,4
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Loss of the
         <em>
          katG
         </em>
         -encoded catalase peroxidase
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Overexpression or alterations in the INH target
         <em>
          InhA
         </em>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Loss of NADH dehydrogenase II activity (
         <em>
          ndh
         </em>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Alterations and overexpression of
         <em>
          KasA
         </em>
        </p>
        <p>
        </p>
        <p>
         Some isolates with low-level INH resistance do not have mutations in these genes, suggesting that additional genes may be involved in INH resistance [
         <a href="#rid5">
          5
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/8027.html" rel="external">
          "Epidemiology and molecular mechanisms of drug-resistant tuberculosis"
         </a>
         .)
        </p>
        <p>
         Newer genotypic methods to detect resistance testing have been developed to detect INH resistance more rapidly; these correlate well with slower, phenotypic methods of resistance detection [
         <a href="#rid6">
          6
         </a>
         ]. However, less frequent mutations conferring resistance may evade such detection [
         <a href="#rid5">
          5
         </a>
         ].
        </p>
        <p>
         In general, drug susceptibility depends on the resistance mechanism. In one report, strains exhibiting only an
         <em>
          InhA
         </em>
         promoter change or a mutation at codon 315 of
         <em>
          katG
         </em>
         had MIC distributions of 0.25 to 2 and 4 to 16 mcg/mL, respectively, while those strains with both mutations exhibited higher MICs (8 to 64 mcg/mL) [
         <a href="#rid4">
          4
         </a>
         ].
        </p>
        <p>
         It may be possible to overcome low-level resistance to INH by increasing the INH dose [
         <a href="#rid7">
          7,8
         </a>
         ]. This approach may be used for treatment of tuberculosis caused by isolates with low-level INH resistance in vitro and evidence of an
         <em>
          inhA
         </em>
         mutation (which is associated with low-level INH resistance) but is unlikely to be beneficial in the presence of a
         <em>
          katG
         </em>
         mutation (which is associated with high-level INH resistance). (See
         <a class="local">
          'Dosing and administration'
         </a>
         below.)
        </p>
        <p>
         In the United States, drug resistance has been observed more frequently among certain patient populations. These include African-Americans, Mexican-Americans, and Indochinese refugees. In 2017, the rate of INH monoresistance among culture-positive cases was 9.2 percent and was higher among foreign-born than United States-born patients (10.7 versus 5.6 percent) [
         <a href="#rid9">
          9
         </a>
         ]. In addition, the rate of INH resistance is higher among patients with a previous history of tuberculosis than among patients with no previous history of tuberculosis (19.9 versus 8.8 percent).
        </p>
        <p>
         Primary INH resistance is more prevalent in resource-limited countries of Southeast Asia, Africa, and Latin America.
        </p>
        <p class="headingAnchor" id="H6642064">
         <span class="h2">
          Pharmacokinetics
         </span>
         <span class="headingEndMark">
          —
         </span>
         INH is well absorbed after oral administration (approximately 90 percent). Peak serum concentrations occurring 0.5 to 2 hours after an oral dose range from 3 to 6 mcg/mL after a 300 mg dose and from 9 to 18 mcg/mL after a 900 mg dose [
         <a href="#rid10">
          10,11
         </a>
         ].
        </p>
        <p>
         Absorption following oral therapy may be delayed or reduced by food and antacids. Limited evidence is available to suggest that patients with HIV infection may exhibit malabsorption of antituberculous agents, including INH [
         <a href="#rid12">
          12
         </a>
         ].
        </p>
        <p>
         INH is widely distributed in the body (including cerebrospinal fluid and breast milk), with a volume of distribution ranging from 0.6 to 1.2 L/kg. Protein binding is low (&lt;10 percent).
        </p>
        <p>
         Acetylation is the main route of INH metabolism, which is genetically determined and differs among ethnic groups. Acetylation rates can vary four- to fivefold [
         <a href="#rid13">
          13
         </a>
         ]. Approximately 50 percent of White and Black individuals are rapid acetylators; in addition, 80 to 90 percent of Asian individuals and native peoples of Alaska and other Arctic regions are rapid acetylators. The elimination half-life ranges from 1 to 1.8 hours in fast acetylators to 3 to 4 hours in slow acetylators [
         <a href="#rid10">
          10
         </a>
         ].
        </p>
        <p>
         In rapid acetylators, use of once-weekly regimens has been associated with higher rates of treatment failure when standard dosing is utilized. For other treatment regimens, acetylator status does not appear to influence the clinical outcome, and testing for acetylator status at initiation of therapy is not routinely performed [
         <a href="#rid14">
          14
         </a>
         ].
        </p>
        <p>
         The major route of elimination is the kidney, with 75 to 96 percent of the dose excreted in urine as unchanged drug or metabolites. Slow acetylators excrete a higher percentage as unchanged drug compared with rapid acetylators (30 to 35 versus 10 percent) [
         <a href="#rid15">
          15
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H6642318">
         <span class="h2">
          Drug interactions
         </span>
         <span class="headingEndMark">
          —
         </span>
         Drug interactions result from the ability of INH to inhibit cytochrome (CYP) CYP2E1 (moderate) and CYP3A4 (weak). Such interactions include (but are not limited to)
         <a class="drug drug_general" data-topicid="9769" href="/z/d/drug information/9769.html" rel="external">
          phenytoin
         </a>
         ,
         <a class="drug drug_general" data-topicid="10281" href="/z/d/drug information/10281.html" rel="external">
          theophylline
         </a>
         ,
         <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">
          carbamazepine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9811" href="/z/d/drug information/9811.html" rel="external">
          primidone
         </a>
         , and
         <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">
          warfarin
         </a>
         . Details about specific interactions may be obtained by using the
         <a class="external" href="/drug-interactions">
          drug interactions program
         </a>
         included within UpToDate.
        </p>
        <p>
         Rare reports have been published of monoamine oxidase inhibitor-like activity resulting from the coadministration of INH with foods containing a high content of tyramine. However, the significance of such interactions and the relevance among fast versus slow acetylators remains to be determined.
        </p>
        <p>
         Early studies suggest that absorption of INH may be reduced by concomitant administration of aluminum-containing antacids. However, this has not been supported by more recent trials [
         <a href="#rid16">
          16-18
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H6642589">
         <span class="h1">
          CLINICAL USE
         </span>
        </p>
        <p class="headingAnchor" id="H6643277">
         <span class="h2">
          Dosing and administration
         </span>
         <span class="headingEndMark">
          —
         </span>
         INH dosing is dependent upon the patient weight, age, indication, and frequency of administration. The usual adult dose of INH is 5 mg/kg orally once daily. Higher single doses (up to 15mg/kg maximum 900mg) are used for intermittent regimens, latent infections and for treatment of multidrug-resistant tuberculosis with low-level INH resistance [
         <a href="#rid14">
          14,19
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/8017.html" rel="external">
          "Treatment of tuberculosis infection (latent tuberculosis) in nonpregnant adults without HIV infection"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8011.html" rel="external">
          "Treatment of tuberculosis infection (latent tuberculosis) in nonpregnant adults with HIV infection"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8015.html" rel="external">
          "Treatment of drug-susceptible pulmonary tuberculosis in nonpregnant adults without HIV infection"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8013.html" rel="external">
          "Treatment of drug-susceptible pulmonary tuberculosis in nonpregnant adults with HIV infection: Initiation of therapy"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8028.html" rel="external">
          "Treatment of drug-resistant pulmonary tuberculosis in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5341.html" rel="external">
          "Treatment of
          <i>
           Mycobacterium avium
          </i>
          complex pulmonary infection in adults"
         </a>
         .)
        </p>
        <p>
         Dosing recommendations for children vary with indication (latent infection versus active disease), frequency of administration, and patient age. (See
         <a class="medical medical_review" href="/z/d/html/8007.html" rel="external">
          "Tuberculosis disease in children: Epidemiology, clinical manifestations, and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8020.html" rel="external">
          "Tuberculosis infection (latent tuberculosis) in children"
         </a>
         .)
        </p>
        <p>
         Oral INH should be administered one hour before or two hours after meals. INH is available in tablet (100 and 300 mg), liquid (50 mg/5 mL), and injectable forms. The liquid formulation in the United States is available in a
         <a class="drug drug_general" data-topicid="9940" href="/z/d/drug information/9940.html" rel="external">
          sorbitol
         </a>
         base and often in combination with
         <a class="drug drug_general" data-topicid="9839" href="/z/d/drug information/9839.html" rel="external">
          pyridoxine
         </a>
         (vitamin B6). The sorbitol in this preparation may induce diarrhea, especially at higher doses. The intramuscular preparation should be administered at the same dose as oral therapy. It has been given intravenously, although it has not been approved by the US Food and Drug Administration for this route. INH is also available in combination preparations, which in the United States may include
         <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">
          rifampin
         </a>
         and
         <a class="drug drug_general" data-topicid="9836" href="/z/d/drug information/9836.html" rel="external">
          pyrazinamide
         </a>
         . These fixed-dose combinations may facilitate compliance but make dose individualization difficult.
        </p>
        <p>
         The risk of peripheral neuropathy can be reduced by concomitant administration of
         <a class="drug drug_general" data-topicid="9839" href="/z/d/drug information/9839.html" rel="external">
          pyridoxine
         </a>
         (vitamin B6). (See
         <a class="local">
          'Adverse reactions'
         </a>
         below and
         <a class="local">
          'Neurologic reactions'
         </a>
         below.)
        </p>
        <p>
         Patients with renal insufficiency do not require a reduction in INH dose; however, they may be more susceptible to development of neuropathy (see
         <a class="local">
          'Neurologic reactions'
         </a>
         below). INH is removed by both hemodialysis and continuous peritoneal dialysis. Among patients on hemodialysis, INH should be administered after the dialysis.
        </p>
        <p>
         Patients with any risk factors for INH toxicity should be considered to have a relative or absolute contraindication to INH therapy. (See
         <a class="local">
          'Hepatotoxicity'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H6642635">
         <span class="h2">
          Clinical monitoring
         </span>
         <span class="headingEndMark">
          —
         </span>
         Issues related to clinical and laboratory monitoring for patients on INH for treatment of latent tuberculosis infection are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/8011.html" rel="external">
          "Treatment of tuberculosis infection (latent tuberculosis) in nonpregnant adults with HIV infection", section on 'Monitoring and adherence'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8017.html" rel="external">
          "Treatment of tuberculosis infection (latent tuberculosis) in nonpregnant adults without HIV infection", section on 'Monitoring and adherence'
         </a>
         .)
        </p>
        <p>
         Issues related to clinical and laboratory monitoring for patients on INH and other antituberculous drugs for treatment of active tuberculosis infection are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/488.html" rel="external">
          "Antituberculous drugs: An overview", section on 'Clinical and laboratory monitoring'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2591187374">
         <span class="h2">
          Serum concentration monitoring
         </span>
         <span class="headingEndMark">
          —
         </span>
         The role of serum INH concentration monitoring is controversial, since serum concentrations in both adults and children receiving standard doses are variable and dependent on acetylator status (high versus low) [
         <a href="#rid11">
          11
         </a>
         ]. In addition, data supporting target ranges for either efficacy or safety are sparse [
         <a href="#rid20">
          20,21
         </a>
         ].
        </p>
        <p>
         Such testing may be most useful in the setting of suspected INH malabsorption or in patients with slow culture conversion despite adherence to the treatment regimen [
         <a href="#rid22">
          22
         </a>
         ]. Patients undergoing treatment for multidrug-resistant tuberculosis should be considered for serum concentration monitoring to minimize the potential for suboptimal drug exposure [
         <a href="#rid14">
          14
         </a>
         ]. While select patient populations (such as those with renal dysfunction, persons living with HIV, and/or diabetes mellitus) are often included in populations prioritized for such monitoring, these conditions are less impactful on variability in INH concentrations.
        </p>
        <p>
         Rather than a defined target concentration range, results of serum concentrations obtained two hours after a stable (1 to 2 week) dose of
         <a class="drug drug_general" data-topicid="8577" href="/z/d/drug information/8577.html" rel="external">
          isoniazid
         </a>
         can be compared to expected concentrations of 3 to 6 mcg/mL after once daily (300mg) dosing and 9 to 15 mcg/mL after higher (900mg) biweekly doses [
         <a href="#rid10">
          10
         </a>
         ]. Such timing, however, may not capture the true peak concentration in those patients with delayed absorption.
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h2">
          Special populations
         </span>
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h3">
          Patients with hepatic dysfunction
         </span>
         <span class="headingEndMark">
          —
         </span>
         INH should be used with caution in patients with hepatic dysfunction since they are at increased risk of INH-induced hepatotoxicity. In patients with severe hepatic dysfunction, use of an alternative regimen is warranted.
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h3">
          Pregnant or breastfeeding patients
         </span>
         <span class="headingEndMark">
          —
         </span>
         Considerations for use of INH in pregnancy are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/8014.html" rel="external">
          "Tuberculosis disease (active tuberculosis) in pregnancy"
         </a>
         .)
        </p>
        <p>
         Excretion of INH in breast milk is thought to be minimal, and the risk of adverse events to the infant of a nursing mother receiving INH is generally considered to be low [
         <a href="#rid23">
          23
         </a>
         ]. Pregnant women receiving INH and breastfeeding infants of mothers receiving INH should receive
         <a class="drug drug_general" data-topicid="9839" href="/z/d/drug information/9839.html" rel="external">
          pyridoxine
         </a>
         supplementation.
        </p>
        <p class="headingAnchor" id="H13">
         <span class="h2">
          Adverse reactions
         </span>
        </p>
        <p class="headingAnchor" id="H14">
         <span class="h3">
          Neurologic reactions
         </span>
         <span class="headingEndMark">
          —
         </span>
         INH competes with vitamin B6 (
         <a class="drug drug_general" data-topicid="9839" href="/z/d/drug information/9839.html" rel="external">
          pyridoxine
         </a>
         ) in its action as a cofactor in the synthesis of synaptic neurotransmitters. Resulting dose-related neurologic side effects include peripheral neuropathy, ataxia, and paresthesia. Such side effects are uncommon in the absence of risk factors. (See
         <a class="medical medical_review" href="/z/d/html/6166.html" rel="external">
          "Overview of acquired peripheral neuropathies in children", section on 'Vitamin deficiency or excess'
         </a>
         .)
        </p>
        <p>
         Patients at increased risk for INH-induced neurotoxicity include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Older adults
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Pregnant or breastfeeding women
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Children
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Individuals who are malnourished
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Individuals with alcohol use disorder
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Individuals with chronic liver disease
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Individuals with renal failure
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Individuals with diabetes
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Individuals with HIV infection (most notably when receiving concomitant administration of INH with antiretrovirals that may exacerbate such effects, such as
         <a class="drug drug_general" data-topicid="9946" href="/z/d/drug information/9946.html" rel="external">
          stavudine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9351" href="/z/d/drug information/9351.html" rel="external">
          didanosine
         </a>
         , and zalcitabine) [
         <a href="#rid24">
          24
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         When prescribing or switching
         <a class="drug drug_general" data-topicid="8577" href="/z/d/drug information/8577.html" rel="external">
          isoniazid
         </a>
         or antiretroviral drugs, clinicians should consider the potential for drug interactions and consult an expert in pharmacology. They should also monitor the patients for therapeutic efficacy and/or concentration-related toxicities.
        </p>
        <p>
         The risk of neurologic side effects can be reduced by concomitant administration of
         <a class="drug drug_general" data-topicid="9839" href="/z/d/drug information/9839.html" rel="external">
          pyridoxine
         </a>
         (vitamin B6). The usual dose is 25 to 50 mg/day (in those with one or more risk factors) [
         <a href="#rid25">
          25
         </a>
         ]. Treatment of INH-induced neuropathies with pyridoxine and those with pre-existing neuropathy should be considered for higher pyridoxine doses (100 to 200 mg/day).
        </p>
        <p class="headingAnchor" id="H6644036">
         <span class="h3">
          Hepatotoxicity
         </span>
         <span class="headingEndMark">
          —
         </span>
         INH-induced hepatotoxicity is probably related to metabolites of INH and is not correlated with serum concentrations of the parent compound. This is most likely due to genetic polymorphisms that affect the metabolic rates of drug enzymes responsible for the production of toxic metabolites [
         <a href="#rid26">
          26,27
         </a>
         ]. The onset of INH-induced hepatotoxicity is observed within the first two months of therapy in approximately 50 percent of patients.
        </p>
        <p>
         The patient risk factors, frequency, clinical manifestations, diagnosis, and management of INH hepatotoxicity are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/477.html" rel="external">
          "Isoniazid hepatotoxicity"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H16">
         <span class="h3">
          Other reactions
         </span>
         <span class="headingEndMark">
          —
         </span>
         Acute INH overdose presents with altered or depressed mental status or seizures, including status epilepticus. This is discussed further separately. (See
         <a class="medical medical_review" href="/z/d/html/316.html" rel="external">
          "Isoniazid (INH) poisoning"
         </a>
         .)
        </p>
        <p>
         INH has been associated with a variety of relatively uncommon complications; these include rheumatologic (including drug-induced lupus syndrome), dermatologic (urticarial rash), gastrointestinal (abdominal pain, nausea, vomiting), and hematologic abnormalities.
        </p>
        <p>
         Diarrhea associated with the liquid preparation is thought to be secondary to
         <a class="drug drug_general" data-topicid="9940" href="/z/d/drug information/9940.html" rel="external">
          sorbitol
         </a>
         contained in the formulation.
        </p>
        <p class="headingAnchor" id="H19">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Beyond the Basics topic (see
         <a class="medical medical_patient" href="/z/d/html/4012.html" rel="external">
          "Patient education: Tuberculosis (Beyond the Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H19410460">
         <span class="h1">
          SUMMARY
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="8577" href="/z/d/drug information/8577.html" rel="external">
          Isoniazid
         </a>
         (INH) is used for treatment of tuberculosis (as part of combination therapy) or for latent tuberculosis infection (as monotherapy or part of combination therapy). Less frequently, INH may be used as part of a combination regimen for nontuberculous mycobacterial infections. (See
         <a class="local">
          'Introduction'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The antimicrobial activity of INH is selective for mycobacteria, likely due to its ability to inhibit mycolic acid synthesis, which interferes with cell wall synthesis, thereby producing a bactericidal effect. (See
         <a class="local">
          'Mechanism of action'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         INH is well absorbed after oral administration (approximately 90 percent) and widely distributed in the body, including cerebrospinal fluid and breast milk. (See
         <a class="local">
          'Pharmacokinetics'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Drug interactions result from the ability of INH to inhibit the cytochrome hepatic enzyme system. Such interactions include (but are not limited to)
         <a class="drug drug_general" data-topicid="9769" href="/z/d/drug information/9769.html" rel="external">
          phenytoin
         </a>
         ,
         <a class="drug drug_general" data-topicid="10281" href="/z/d/drug information/10281.html" rel="external">
          theophylline
         </a>
         ,
         <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">
          carbamazepine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9811" href="/z/d/drug information/9811.html" rel="external">
          primidone
         </a>
         , and
         <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">
          warfarin
         </a>
         . (See
         <a class="local">
          'Drug interactions'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Dosing of INH varies with indication, patient age, and frequency of administration. (See
         <a class="local">
          'Dosing and administration'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         INH should be used with caution in patients with hepatic dysfunction, since they are at increased risk of INH-induced hepatotoxicity. (See
         <a class="local">
          'Patients with hepatic dysfunction'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         INH is generally considered safe for use in pregnant patients. Excretion in breast milk is thought to be minimal, and the risk of adverse events to the infant of a nursing mother receiving INH is generally considered to be low.
         <a class="drug drug_general" data-topicid="9839" href="/z/d/drug information/9839.html" rel="external">
          Pyridoxine
         </a>
         supplementation is recommended for pregnant women and breastfeeding infants of mothers receiving INH. (See
         <a class="local">
          'Pregnant or breastfeeding patients'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         INH competes with vitamin B6 (
         <a class="drug drug_general" data-topicid="9839" href="/z/d/drug information/9839.html" rel="external">
          pyridoxine
         </a>
         ) in its action as a cofactor in the synthesis of synaptic neurotransmitters. Resulting dose-related neurologic side effects include peripheral neuropathy, ataxia, and paresthesia. Neurotoxicity can be prevented by pyridoxine supplementation in most patients. (See
         <a class="local">
          'Neurologic reactions'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Issues related to clinical and laboratory monitoring for patients on INH are discussed separately. (See
         <a class="local">
          'Clinical monitoring'
         </a>
         above.)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li class="breakAll">
          Berning SE, Peloquin CA. Antimycobacterial agents: Isoniazid. In: Antimicrobial Therapy and Vaccines, Yu V, Merigan T, Barriere S (Eds), Williams and Wilkins, Baltimore 1998.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schön T, Juréen P, Giske CG, et al. Evaluation of wild-type MIC distributions as a tool for determination of clinical breakpoints for Mycobacterium tuberculosis. J Antimicrob Chemother 2009; 64:786.
          </a>
         </li>
         <li class="breakAll">
          Zhang Y, Vilcheze C, Jacobs WR. Mechanisms of drug resistance in Mycobacterium tuberculosis. In: Tuberculosis and the Tubercle Bacillus, Cole ST, Eisenach KD, McMurray DN, Jacobs WR (Eds), ASM Press, Washington, DC 2005.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ghodousi A, Tagliani E, Karunaratne E, et al. Isoniazid Resistance in Mycobacterium tuberculosis Is a Heterogeneous Phenotype Composed of Overlapping MIC Distributions with Different Underlying Resistance Mechanisms. Antimicrob Agents Chemother 2019; 63.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Valafar SJ. Systematic Review of Mutations Associated with Isoniazid Resistance Points to Continuing Evolution and Subsequent Evasion of Molecular Detection, and Potential for Emergence of Multidrug Resistance in Clinical Strains of Mycobacterium tuberculosis. Antimicrob Agents Chemother 2021; 65.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           CRyPTIC Consortium and the 100,000 Genomes Project, Allix-Béguec C, Arandjelovic I, et al. Prediction of Susceptibility to First-Line Tuberculosis Drugs by DNA Sequencing. N Engl J Med 2018; 379:1403.
          </a>
         </li>
         <li class="breakAll">
          Curry International Tuberculosis Center. Drug-Resistant Tuberculosis: A Survival Guide for Clinicians, Third Edition. CITC, Washington, DC 2016. http://www.currytbcenter.ucsf.edu/sites/default/files/tb_sg3_book.pdf (Accessed on July 12, 2016).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dooley KE, Miyahara S, von Groote-Bidlingmaier F, et al. Early Bactericidal Activity of Different Isoniazid Doses for Drug-Resistant Tuberculosis (INHindsight): A Randomized, Open-Label Clinical Trial. Am J Respir Crit Care Med 2020; 201:1416.
          </a>
         </li>
         <li class="breakAll">
          Centers for Disease Control and Prevention. Reported tuberculosis in the United States, 2017. Table 15. https://www.cdc.gov/tb/statistics/reports/2017/2017_Surveillance_FullReport.pdf (Accessed on March 08, 2019).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alsultan A, Peloquin CA. Therapeutic drug monitoring in the treatment of tuberculosis: an update. Drugs 2014; 74:839.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sturkenboom MGG, Märtson AG, Svensson EM, et al. Population Pharmacokinetics and Bayesian Dose Adjustment to Advance TDM of Anti-TB Drugs. Clin Pharmacokinet 2021; 60:685.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sahai J, Gallicano K, Swick L, et al. Reduced plasma concentrations of antituberculosis drugs in patients with HIV infection. Ann Intern Med 1997; 127:289.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weber WW, Hein DW. Clinical pharmacokinetics of isoniazid. Clin Pharmacokinet 1979; 4:401.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nahid P, Dorman SE, Alipanah N, et al. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis. Clin Infect Dis 2016; 63:e147.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ellard GA, Gammon PT. Pharmacokinetics of isoniazid metabolism in man. J Pharmacokinet Biopharm 1976; 4:83.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lin MY, Lin SJ, Chan LC, Lu YC. Impact of food and antacids on the pharmacokinetics of anti-tuberculosis drugs: systematic review and meta-analysis. Int J Tuberc Lung Dis 2010; 14:806.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hurwitz A, Schlozman DL. Effects of antacids on gastrointestinal absorption of isoniazid in rat and man. Am Rev Respir Dis 1974; 109:41.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gallicano K, Sahai J, Zaror-Behrens G, Pakuts A. Effect of antacids in didanosine tablet on bioavailability of isoniazid. Antimicrob Agents Chemother 1994; 38:894.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sterling TR, Njie G, Zenner D, et al. Guidelines for the Treatment of Latent Tuberculosis Infection: Recommendations from the National Tuberculosis Controllers Association and CDC, 2020. MMWR Recomm Rep 2020; 69:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Burhan E, Ruesen C, Ruslami R, et al. Isoniazid, rifampin, and pyrazinamide plasma concentrations in relation to treatment response in Indonesian pulmonary tuberculosis patients. Antimicrob Agents Chemother 2013; 57:3614.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aït Moussa L, El Bouazzi O, Serragui S, et al. Rifampicin and isoniazid plasma concentrations in relation to adverse reactions in tuberculosis patients: a retrospective analysis. Ther Adv Drug Saf 2016; 7:239.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kim HW, Shin AY, Ha JH, et al. Effect of serum isoniazid level on treatment outcomes among tuberculosis patients with slow response - A retrospective cohort study. J Infect Chemother 2021; 27:1555.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Garessus EDG, Mielke H, Gundert-Remy U. Exposure of Infants to Isoniazid via Breast Milk After Maternal Drug Intake of Recommended Doses Is Clinically Insignificant Irrespective of Metaboliser Status. A Physiologically-Based Pharmacokinetic (PBPK) Modelling Approach to Estimate Drug Exposure of Infants via Breast-Feeding. Front Pharmacol 2019; 10:5.
          </a>
         </li>
         <li class="breakAll">
          Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. NIH Office of Aids Research, 2023. Available at: https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-arv/drug-interactions-overview (Accessed on October 31, 2023).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Prevention and treatment of tuberculosis among patients infected with human immunodeficiency virus: principles of therapy and revised recommendations. Centers for Disease Control and Prevention. MMWR Recomm Rep 1998; 47:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Erwin ER, Addison AP, John SF, et al. Pharmacokinetics of isoniazid: The good, the bad, and the alternatives. Tuberculosis (Edinb) 2019; 116S:S66.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Khan S, Mandal RK, Elasbali AM, et al. Pharmacogenetic association between NAT2 gene polymorphisms and isoniazid induced hepatotoxicity: trial sequence meta-analysis as evidence. Biosci Rep 2019; 39.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 481 Version 31.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Berning SE, Peloquin CA. Antimycobacterial agents: Isoniazid. In: Antimicrobial Therapy and Vaccines, Yu V, Merigan T, Barriere S (Eds), Williams and Wilkins, Baltimore 1998.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19633001" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Evaluation of wild-type MIC distributions as a tool for determination of clinical breakpoints for Mycobacterium tuberculosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19633001" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Evaluation of wild-type MIC distributions as a tool for determination of clinical breakpoints for Mycobacterium tuberculosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31010866" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Isoniazid Resistance in Mycobacterium tuberculosis Is a Heterogeneous Phenotype Composed of Overlapping MIC Distributions with Different Underlying Resistance Mechanisms.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33361298" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Systematic Review of Mutations Associated with Isoniazid Resistance Points to Continuing Evolution and Subsequent Evasion of Molecular Detection, and Potential for Emergence of Multidrug Resistance in Clinical Strains of Mycobacterium tuberculosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30280646" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Prediction of Susceptibility to First-Line Tuberculosis Drugs by DNA Sequencing.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30280646" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Prediction of Susceptibility to First-Line Tuberculosis Drugs by DNA Sequencing.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31945300" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Early Bactericidal Activity of Different Isoniazid Doses for Drug-Resistant Tuberculosis (INHindsight): A Randomized, Open-Label Clinical Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31945300" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Early Bactericidal Activity of Different Isoniazid Doses for Drug-Resistant Tuberculosis (INHindsight): A Randomized, Open-Label Clinical Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24846578" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Therapeutic drug monitoring in the treatment of tuberculosis: an update.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33674941" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Population Pharmacokinetics and Bayesian Dose Adjustment to Advance TDM of Anti-TB Drugs.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9265429" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Reduced plasma concentrations of antituberculosis drugs in patients with HIV infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/391461" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Clinical pharmacokinetics of isoniazid.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27516382" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/950592" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Pharmacokinetics of isoniazid metabolism in man.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20550762" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Impact of food and antacids on the pharmacokinetics of anti-tuberculosis drugs: systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4588090" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Effects of antacids on gastrointestinal absorption of isoniazid in rat and man.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8031068" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Effect of antacids in didanosine tablet on bioavailability of isoniazid.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32053584" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Guidelines for the Treatment of Latent Tuberculosis Infection: Recommendations from the National Tuberculosis Controllers Association and CDC, 2020.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23689725" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Isoniazid, rifampin, and pyrazinamide plasma concentrations in relation to treatment response in Indonesian pulmonary tuberculosis patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27904742" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Rifampicin and isoniazid plasma concentrations in relation to adverse reactions in tuberculosis patients: a retrospective analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34238662" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Effect of serum isoniazid level on treatment outcomes among tuberculosis patients with slow response - A retrospective cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30723406" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Exposure of Infants to Isoniazid via Breast Milk After Maternal Drug Intake of Recommended Doses Is Clinically Insignificant Irrespective of Metaboliser Status. A Physiologically-Based Pharmacokinetic (PBPK) Modelling Approach to Estimate Drug Exposure of Infants via Breast-Feeding.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30723406" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Exposure of Infants to Isoniazid via Breast Milk After Maternal Drug Intake of Recommended Doses Is Clinically Insignificant Irrespective of Metaboliser Status. A Physiologically-Based Pharmacokinetic (PBPK) Modelling Approach to Estimate Drug Exposure of Infants via Breast-Feeding.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9809743" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Prevention and treatment of tuberculosis among patients infected with human immunodeficiency virus: principles of therapy and revised recommendations. Centers for Disease Control and Prevention.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31076322" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Pharmacokinetics of isoniazid: The good, the bad, and the alternatives.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30509962" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Pharmacogenetic association between NAT2 gene polymorphisms and isoniazid induced hepatotoxicity: trial sequence meta-analysis as evidence.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
